MicroStrategy
MSTR
英偉達
NVDA
Adobe
ADBE
賽富時
CRM
蘋果
AAPL
美股市場個股詳情
BPMC Blueprint Medicines
- 90.140
- +1.210+1.36%
收盤價 12/20 16:00 (美東)
- 90.000
- -0.140-0.16%
盤後 16:55 (美東)
57.26億總市值-43.13市盈率TTM
90.990最高價87.990最低價126.74萬股成交量88.120今開88.930昨收1.14億成交額2.02%換手率虧損市盈率(靜)6352.58萬總股本121.90052周最高18.29市淨率56.65億流通值72.24052周最低--股息TTM6284.50萬流通股125.610歷史最高--股息率TTM3.37%振幅13.040歷史最低89.890平均價1股每手
關於Blueprint Medicines公司
藍圖醫藥公司是一家生物製藥公司。它專注於改善由異常激酶激活引起的疾病患者的生活。該公司開發了針對癌症和罕見遺傳病的小分子藥物管線。其候選藥物包括用於治療系統性肥大細胞增多症的AYVAKIT，BLU-808，一種治療肥大細胞疾病（包括慢性蕁麻疹、睡眠中斷和其他相關疾病）的潛在藥物。該公司還有其他藥物正在研發中，例如用於治療乳腺癌的BLU-956、BLU-222。
公司介紹
公司代碼BPMC
公司名稱Blueprint Medicines
上市日期2015/04/30
發行價格18.00
成立日期2008
CEOMs. Kathryn Haviland
所屬市場納斯達克
員工數量655
年結日12-31
公司地址45 Sidney Street
城市Cambridge
省份麻塞諸塞州
國家美國
郵編02139
電話1-617-374-7580
董事高管
- 姓名
- 職務
- 年薪
- Kathryn Haviland
- Director, President and Chief Executive Officer
- 643.20萬
- Debra Durso-Bumpus
- Chief People Officer
- --
- Michael Landsittel, M.B.A.
- Chief Financial Officer
- 219.48萬
- Dr. Philina Lee, PhD
- Chief Commercial Officer
- --
- Tracey L. McCain, Esq.
- Chief Legal and Compliance Officer
- --
- Christina Rossi, M.B.A.
- Chief Operating Officer
- 280.62萬
- Dr. Becker Hewes, M.D.
- Chief Medical Officer
- --
- Dr. Percy H. Carter, M.B.A.,PhD
- Chief Scientific Officer
- 229.98萬
- Dr. Christopher K. Murray, PhD
- Chief Technical Operations and Quality Officer
- --
- Ariel Hurley
- Senior Vice President, Finance and Principal Accounting Officer
- --
- Jeffrey W. Albers, J.D.
- Chairman of the Board
- 52.61萬
- Dr. Fouad Namouni, M.D.
- President, Research and Development
- 280.18萬
- Alexis A. Borisy, A.M.
- Director
- 39.73萬
- Dr. John Tsai, M.D.
- Independent Director
- 76.98萬
- Dr. Mark Alan Goldberg, M.D.
- Independent Director
- 41.93萬
- Habib Joseph Dable
- Independent Director
- 41.23萬
- Dr. Lynn Seely,M.D.
- Lead Independent Director
- 45.23萬
- Dr. Nicholas Lydon, F.R.S.,PhD
- Independent Director
- 41.73萬
- Lonnel Coats
- Independent Director
- 41.93萬
- Daniella Beckman
- Independent Director
- 42.23萬
